title: Zinc levels in serum during subcutaneous interleukin-2 immunotherapy of cancer.
authors.forename: P
authors.initials: P
authors.lastname: Lissoni
authors.forename: V
authors.initials: V
authors.lastname: Arosio
authors.forename: E
authors.initials: E
authors.lastname: Mocchegiani
authors.forename: N
authors.initials: N
authors.lastname: Fabris
authors.forename: S
authors.initials: S
authors.lastname: Barni
authors.forename: W
authors.initials: W
authors.lastname: Pierpaoli
authors.forename: G
authors.initials: G
authors.lastname: Tancini
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000556:secondary / Q000628:therapy; D002940:Circadian Rhythm / Q000187:drug effects; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D007167:Immunotherapy; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000097:blood* / Q000628:therapy; D008297:Male; D008550:Melatonin / Q000378:metabolism; D008875:Middle Aged; D010870:Pineal Gland / Q000187:drug effects / Q000378:metabolism; D015032:Zinc / Q000097:blood* / Q000172:deficiency
chemical_list: D015415:Biomarkers; D007155:Immunologic Factors; D007376:Interleukin-2; D015032:Zinc; D008550:Melatonin